Open Access

Recurrent Scedosporium apiospermum mycetoma successfully treated by surgical excision and terbinafine treatment: a case report and review of the literature

  • Eszter J. Tóth1, 2,
  • Géza R. Nagy3,
  • Mónika Homa1, 2,
  • Marianna Ábrók4,
  • Ildikó É. Kiss4,
  • Gábor Nagy1, 2,
  • Zsuzsanna Bata-Csörgő3,
  • Lajos Kemény3,
  • Edit Urbán4,
  • Csaba Vágvölgyi2 and
  • Tamás Papp1, 2Email author
Annals of Clinical Microbiology and Antimicrobials201716:31

https://doi.org/10.1186/s12941-017-0195-z

Received: 28 January 2017

Accepted: 21 March 2017

Published: 14 April 2017

Abstract

Background

Scedosporium apiospermum is an emerging opportunistic filamentous fungus, which is notorious for its high levels of antifungal-resistance. It is able to cause localized cutaneous or subcutaneous infections in both immunocompromised and immunocompetent persons, pulmonary infections in patients with predisposing pulmonary diseases and invasive mycoses in immunocompromised patients. Subcutaneous infections caused by this fungus frequently show chronic mycetomatous manifestation.

Case report

We report the case of a 70-year-old immunocompromised man, who developed a fungal mycetomatous infection on his right leg. There was no history of trauma; the aetiological agent was identified by microscopic examination and ITS sequencing. This is the second reported case of S. apiospermum subcutaneous infections in Hungary, which was successfully treated by surgical excision and terbinafine treatment. After 7 months, the patient remained asymptomatic. Considering the antifungal susceptibility and increasing incidence of the fungus, Scedosporium related subcutaneous infections reported in the past quarter of century in European countries were also reviewed.

Conclusions

Corticosteroid treatment represents a serious risk factor of S. apiospermum infections, especially if the patient get in touch with manure-enriched or polluted soil or water. Such infections have emerged several times in European countries in the past decades. The presented data suggest that besides the commonly applied voriconazole, terbinafine may be an alternative for the therapy of mycetomatous Scedosporium infections.

Keywords

Filamentous fungi Cutaneous infection Antifungal susceptibility Immunosuppression Corticosteroid therapy Scedosporium apiospermum

Background

Scedosporium apiospermum is a ubiquitous, saprophytic filamentous fungus, which can be isolated mainly from environments affected by human activity (i.e. manure-enriched or polluted soils and water) [1]. It is an emerging opportunist that can cause trauma-associated, localized infections, colonization of pulmonary cavities in patients with predisposing pulmonary disorders (such as cystic fibrosis) and systemic invasive diseases in immunocompromised patients [2]. This mould is notorious for its therapy-refractory nature and resistance for several antifungal agents [1, 3]. Traumatic localized infections can occur in both immunocompromised and immunocompetent persons and are most frequently manifested as mycetomatous, chronic progressive subcutaneous infections, which may also reach the muscles and the bones [1]. Scedosporium-caused mycetomas can be found worldwide but most cases have been reported in western Europe, Australia and North America [46]. Here, we report a Hungarian patient with recurrent mycetomatous S. apiospermum infection successfully treated by surgical excision and terbinafine treatment and review the similar cases reported during the past 2 decades in Europe.

Case presentation

A 70-year-old man, who worked at a vegetable plantation in previous years, was admitted to our institution with severe edema on the lower right leg and foot, accompanied by pain, fever (38.3 °C), erythema, numerous small-sized papules and abscesses. There was no medical history of notable trauma, however the patient did undergo a prosthesis implantation surgery of the right knee, 10 years ago.

In the previous year, he was hospitalized because of melena and anemia. The patient was given 8 units of red blood cell transfusions and underwent gastroscopy, colonoscopy and abdominal computed tomography angiography. Comprehensive gastrointestinal examination found no source of bleeding, however, laboratory tests showed significant proteinuria (10 g/day), low albumin (22 g/L) and IgG (5.24 g/L) levels. A kidney biopsy was performed, which revealed focal segmental glomerulosclerosis. Owing to the possibility of myeloma multiplex and amyloidosis, additional tests were also carried out with negative results. Based on these findings, the patient was diagnosed with nephrotic syndrome and received corticosteroid pulse therapy (3 × 750 mg) intravenously, which was then switched to oral administration. In the following weeks, the corticosteroid dose was gradually reduced from 80 to 16–8 mg, without any complications.

Three months later, he developed fever (38.3 °C), swelling and erythema on both legs. In addition, small petechiae could also be observed on his arms, torso and right knee, which was interpreted as vasculitis caused by the patient’s septic state. Laboratory results displayed profoundly high C-reactive protein (CRP; 354.9 mg/L) level and erythrocyte sedimentation rate (94 mm/h). Based on the clinical symptoms, erysipelas and sepsis were considered to be the initial diagnoses and the patient was put on a course of antibiotic treatment (3 × 1.2 g amoxicillin and clavulanic acid). After 4 days, subsequent laboratory values for CRP and erythrocyte sedimentation rate showed 76.8 mg/L and 84 mm/h, respectively.

After 2 weeks, however, the patient was referred to our clinic, owing to the progression in his cutaneous symptoms. The patient then presented with a severely oedemic and painful lower right leg, with slight erythema and multiple small soft papules (Fig. 1). In addition, the whole skin of this extremity had a sponge-like feel to the touch. No notable symptoms were present on the left leg. Laboratory tests showed elevated CRP (38 mg/L) and high white blood cell count (12.85 × 109/L). Ultrasound revealed four 10–13 mm-sized subcutaneous collections of echogenic fluid in the right leg. After incision and drainage of these lesions, swabs were sent to the microbiological laboratory for culturing. Only Scedosporium apiospermum grew in culture after 3 days of incubation at normal atmosphere at 30 °C. After accurate morphological assessment, the sample was sent for additional identification by DNA sequencing.
Fig. 1

Edema, erythema and small superficial abscesses (white arrows) on the lower right leg and foot

Considering this finding, instead of the initially administered penicillin-type antibiotic, the patient was given fluconazole (200 mg) intravenously on six occasions, to which his symptoms markedly improved. Subsequently, taking the patient’s low glomerular filtration rate (56 mL/min) into account, he was prescribed a synthetic allylamine antifungal medication (250 mg terbinafine) to take every second day with the aim of minimizing potential side effects and underwent several other abscess drainages in the following weeks, in addition to the local antimicrobial agents (i.e. betadine, hydrogen peroxide, and boric acid powder). Parallel with his treatment for the mycotic infection, his steroid therapy dose was gradually decreased and his nephrotic syndrome improved. Two months into his treatment, he experienced a recurrent infection on the right leg. At this time, no mycotic infection could be proven, as only Staphylococcus aureus was cultured from multiple small superficial abscesses, thus the patient received a combination antibiotic of piperacillin and tazobactam (3 × 4.5 g) for a week, followed by amoxicillin and clavulanic acid (4 × 1.2 g) for another week, to which his symptoms regressed.

Though edema of the right leg persisted even after many months, there were no longer any clinical signs of inflammation and the patient did not experience any pain. Leukocyte scintigraphy displayed increased activity around the right ankle, suggesting the development of a new abscess, but it was successfully managed with antibiotic and local treatment. After 7 months, the patient remained asymptomatic and currently maintains a low dose of corticosteroid (4 mg/day) therapy. In addition to occupational exposure, low serum IgG levels and the immunosuppressive effect of the corticosteroid treatment were most likely compelling factors in further substantiating the likelihood of this rare fungal infection in our patient’s case.

Mycological investigations

The isolate was deposited in the Szeged Microbiology Collection (SZMC; http://www.wfcc.info/ccinfo/collection/by_id/987) with the strain number SZMC 23374 and was sub-cultured on malt extract agar (MEA; 5% malt extract, 1% glucose, 2% agar) plates at 37 °C for further morphological and molecular examinations. It formed greyish–white, cotton-like colonies on MEA (Fig. 2a). Microscopic examination revealed branched hyphae with clavate or ovoid conidia born singly on simple or branched conidiophores or laterally on the hyphae (Fig. 2b).
Fig. 2

Colony (a) and micromorphology (b) of Scedosporium apiospermum isolate SZMC 23374. Scale bar 10 µm

For molecular identification, genomic DNA was extracted from 10 mg of mycelium ground to a fine powder in liquid nitrogen and purified by using the MasterPure Yeast DNA purification kit (Epicentre, USA) according to the instructions of the manufacturer. The complete ITS (internal transcribed spacer, including ITS1-5.8S rRNA-ITS2) region was amplified by PCR, using the primers ITS1 and ITS4 [7]. The resulting amplicons were sequenced at LGC Genomics (Germany). The determined sequence was deposited in the European Nucleotide Archive (ENA, http://www.ebi.ac.uk/ena) database (Accession number: LT703449) and used for similarity searches in the NCBI database using the BLASTN algorithm (http://blast.ncbi.nlm.nih.gov/Blast.cgi), which confirmed the fungus as S. apiospermum (identities for the whole ITS region, 99%).

In vitro susceptibility of the S. apiospermum isolate to amphotericin B (AMB), fluconazole (FLC), itraconazole (ITC), voriconazole (VRC), caspofungin (CSP), natamycin (NTM) and terbinafine (TRB) (Sigma-Aldrich, USA) was tested using the broth microdilution method according to the CLSI guideline M38-A2 [8]. Minimal inhibitory concentration (MIC) values were determined in 96-well microtiter plates by visual inspection of the cultures after 72 h incubation at 37 °C in standard RPMI-1640 medium (Sigma-Aldrich, USA). Inocula were prepared from 14-day cultures grown on MEA; the final conidial suspensions contained 104 CFU/mL. Final concentrations of the drugs ranged from 0.5 to 256 μg/mL. Each plate contained a sterile control (containing medium alone) and a growth control (containing inoculated medium without the drugs). Each experiment was performed in triplicates; Paecilomyces variotii ATCC 22319 was used as the quality control strain. Table 1 shows the antifungal susceptibility of the case isolate to the most frequently used antifungal agents. The strain showed low susceptibility to AMB, CSP, ITC and TRB. FLC and NTM proved to be ineffective against the isolate in the investigated concentration range (MIC >128 μg/mL). It was the most susceptible to VRC (MIC 2 μg/mL).
Table 1

MIC values (μg/mL) of antifungal drugs to the S. apiospermum isolate SZMC 23374

Aetiological agent

MIC (µg/mL)

AMB

CSP

FLC

ITC

NTM

TRB

VRC

S. apiospermum

16

32

>256

32

>128

64

2

AMB amphotericin B, CSP caspofungin, FLC fluconazole, ITC itraconazole, NTM natamycin, TRB terbinafine, VRC voriconazole

Discussion

Mycetoma (syn. Madura foot) is the infection of the skin and subcutaneous tissues, which usually develops after a traumatic event of the leg or the foot. It is endemic in tropical and subtropical countries, but rarely reported from temperate regions, as well. Based on the causative agents, the disease can be divided into two categories: actinomycetoma or actinomycosis is caused by Actinomycetes, while eumycetoma or maduramycosis is caused by filamentous fungi [2].

Scedosporium apiospermum was first isolated in 1909 as the aetiological agent of a white grain mycetoma in Sardinia by Tarozzi [9, 10]. This species was considered to be the anamorph of Scedosporium boydii (previously known as Pseudallescheria boydii) until 2005, when they proved to be two distinct species based on molecular, physiological and biochemical data [11]. According to the latest molecular studies S. apiospermum is a species complex, comprising five distinct species: S. apiospermum, Scedosporium aurantiacum, S. boydii, Scedosporium minutisporum, and Scedosporium dehoogii. Out of them, S. apiospermum, S. aurantiacum and S. boydii, are regularly isolated from human infections [12]. Their incidence seems to be increasing, especially among immunocompromised patients. After Aspergillus fumigatus, S. apiospermum and S. boydii are the second most frequently isolated moulds in cystic fibrosis patients [13].

Based on the available case reports in English and Spanish in the PubMed (http://www.ncbi.nlm.nih.gov/pubmed) and Google Scholar (https://scholar.google.hu/) databases, 20 cases of mycetoma or subcutaneous infections were reported due to Scedosporium species between 1992 and 2015 from ten European countries: 4–4 from Germany and the UK, 2–2 from The Netherlands, Spain, France, and Turkey and 1–1 from Italy, Serbia, Slovenia, and Hungary [1432] (Table 2; Fig. 3). Two additional cases have been diagnosed in France, but these patients arrived from outside of Europe (Ivory Coast and Martinique) for hospitalization [33, 34] (not included in Table 2). Of the 20 European cases, 15 were registered in immunosuppressed patients having different underlying conditions, such as organ transplantations, acute myeloid leukemia (AML) or chronic obstructive pulmonary disease (COPD). Similarly to the presented case, out of these patients, 12 had been given a corticosteroid treatment. Although it was not yet proven that these drugs would play a role in the development of Scedosporium infections not just as immunosuppressants but as fungal growth stimulators as well, hydrocortisone has previously proven to enhance the growth of Aspergilli [35]. Taking into account that the patient in the present case had worked with manured garden soil during the corticosteroid therapy, characteristic preference of the fungus for such eutrophic and manure-enriched environments [1] could also represent a serious risk factor for the patient besides the corticosteroid treatment.
Table 2

Subcutaneous infections caused by Scedosporium species in Europe since 1990

Age, gender

Immune status

Predisposing conditions

Signs, symptoms

Aetiological agent

Site of infection

Therapy

Outcome

References

The Netherlands

 59, M

Immunosupp.

Renal transplantation, IV catheter

Purple nodules, slight desquamation

S. apiospermum

Left hand and lower arm

VRC

Recovered

[14]

 84, M

Immunosupp.

COPD, Periprosthetic fracture

Inflammation with bullae

S. apiospermum

Right elbow

VRC

Death after good initial response

[14]

Germany

 24, M

Immunocomp.

Fracture of the tibia

Edematous swellings

S. boydii, Nocardia abscessus

Lower left leg

ITC

Recovered

[15]

 58, M

Immunosupp.

Chronic glomerulonephritis, Renal transplantation, Insect sting

Painful, swollen induration

S. apiospermum

Right forefoot

MCZ, Vacuum seal and suction technique

Recovered

[16]

 15, M

Immunosupp.

Lupus erythematodes, Tibia and fibula fracture

Swelling, impaired wound healing

S. boydii

Lower leg

VRC

Recovered

[17]

 53, F

Immunosupp.

AML

Reddish, inflammatory, painless tumor with central necrosis

S. apiospermum

Right forearm

CSP, VRC

Recovered

[18]

Spain

 58, M

Immunosupp.

Chronic glomerulonephritis

Fever, cutaneous lesions

S. apiospermum

Both legs

VRC

Recovered

[19]

 51, M

Immunosupp.

Renal transplantation

Nodular lesions

S. apiospermum

Left heel

ITC, SI

Recovered

[20]

France

 79, M

Immunosupp.

Bronchospasm

Fever, bullous and necrotic purpura

S. apiospermum

n.a.

ITC

Death (due to Pseudomonas lung infection)

[21]

 65, M

Immunosupp.

COPD, IV catheter

Purple nodules, slight desquamation

S. apiospermum

Left wrist and lower arm

VRC

Recovered

[22]

UK

 51, M

Immunocomp.

Stepped in a dung fork

Swollen, painful foot

S. boydii

Foot (bone involvement)

ITC

Recovered

[23]

 71, M

Immunosupp.

AML

Painful, swollen, erythematous foot, necrotic ulcer between toes

S. apiospermum

Right foot

ITC

Recovered

[24]

 81, M

Immunosupp.

Renal impairment, Pulmonary fibrosis, Scratch from a bush.

Tender subcutaneous nodules

S. apiospermum

Left forearm (joint involvement)

ITC

No follow up

[25]

 35, M

Immunocomp.

na

Painless swelling

S. apiospermum

Right ankle

VRC

Recovered

[26]

Italy

 59, F

Immunosupp.

Renal transplantation

Pain, Achilles tendonitis

S. apiospermum

Skin, knee, and Achilles tendon of the left leg

VRC

Recovered

[27]

Serbia

 50, F

Immunocomp.

na

Pain, indurations, local redness

S. boydii

Soft tissue and bone involvement

SI

Recovered

[28]

Slovenia

 64, M

Immunosupp.

Microscopic polyangiitis

Swelling, pain

S. boydii

Left leg and foot

VRC

Recovered

[29]

Turkey

 48, M

Immunocomp.

na

Swelling

Bacteria, S. boydii

Right hand

Amputation

Recovered

[30]

 62, F

Immunosupp.

Renal transplantation

Edema, erythema, painful, indurated lesion

S. boydii

Left leg

ITC

Recovered

[31]

Hungary

 63, M

Immunosupp.

AML

Swelling, tenderness

S. apiospermum

Lower left leg

ITC

Recovered

[32]

 70, M

Immunosupp.

Nephrotic syndrome

Pain, edema, fever, erythema

S. apiospermum

Lower right leg and foot

TRB, SI

Recovered

Present case

AML acute myeloid leukemia, COPD chronic obstructive pulmonary disease, CSP caspofungin, F female, Immunocomp. immunocompetent, Immunosupp. immunosuppressed, ITC itraconazole, IV intravenous, M male, MCZ miconazole, na not available, SI surgical intervention, TRB terbinafine, VRC voriconazole

Fig. 3

Distribution of subcutaneous Scedosporium infections in Europe since 1990

The causative agents were identified as S. apiospermum and S. boydii in 15 and 7 cases, respectively. While, coinfections of Scedosporia and bacteria (i.e. Nocardia abscessus or unidentified Gram+ and Gram− bacteria) were recorded in two cases [15, 30]. However, the real incidence of the two species is unknown, since much of the case reports have been published before 2005 and mention S. boydii and S. apiospermum as the sexual and asexual form of the same organism. It is also worth to mention that according to a recent case study of Chen et al. [13], the discrimination of S. apiospermum and S. boydii does not result in a different therapeutic approach.

Sixteen of the cases identified in our literature review had positive outcome, one patient did not show up for follow-up examinations, while in another case, the infected limb has been amputated. In addition to these, two fatal cases have also been recorded, however they could not be connected to the infections caused by Scedosporia. Based on the summarized literature data in Table 2, the most common successfully applied medical therapy involved azole antifungals, i.e. voriconazole or itraconazole. Reimann et al. [16] achieved improvement using miconazole combined with vacuum seal and suction technique. Combination antifungal therapy was reported in one case, when after a failed treatment with fluconazole and liposomal amphotericin B, the patient was cured successfully with the combination of voriconazole and caspofungin [18]. Surgical excision alone without antifungal therapy was applied in one case [28], while amputation without attempting any antifungal treatment was performed once in Turkey [30]. Medical therapy (itraconazole) plus surgery was used in the case reported by Montero et al. [20]. Amphotericin B has been applied several times, but it has always been replaced by other antifungals due to its toxicity or ineffectiveness. Based on these data, the treatment applied in the present case is unique in the European literature, since terbinafine alone or in combination with other antifungals or surgical intervention has not been applied successfully for the treatment of S. apiospermum mycetoma before. Although, an S. apiospermum skin infection has been successfully treated by terbinafine combined with voriconazole and surgical excision in Spain [36].

We also would like to highlight here that the patient responded well to terbinafine treatment, despite the relatively high in vitro MIC of the drug. A similar phenomenon was observed by Cunningham and Mitchell [24] in case of amphotericin B. These findings underline the need to handle with care the in vitro antifungal susceptibility data in the clinical treatment of filamentous fungi.

Abbreviations

AMB: 

amphotericin B

AML: 

acute myeloid leukemia

COPD: 

chronic obstructive pulmonary disease

CRP: 

C-reactive protein

CSP: 

caspofungin

ENA: 

European nucleotide archive

FLC: 

fluconazole

ITC: 

itraconazole

ITS: 

internal transcribed spacer

MEA: 

malt extract agar

MIC: 

minimal inhibitory concentration

NTM: 

natamycin

TRB: 

terbinafine

VRC: 

voriconazole

SZMC: 

Szeged microbiology collection

Declarations

Authors’ contributions

TP coordinated the study and participated in design and writing of the manuscript. ET, GN, MH and VC participated in the morphological and molecular identification, antifungal susceptibility testing and drafting the manuscript. MÁ, IÉK, and EU isolated the fungus and participated in its microbiological characterization. GRN, LK and ZB-C performed the management of the patient and participated in the isolation of the aetiological agent. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

All data generated or analysed during this study are included in this published article or available from the corresponding author on reasonable request.

Funding

This study was supported by the “Momentum” Grant of the Hungarian Academy of Sciences (LP2016-8/2016) and the project GINOP-2.3.2-15-2016-00035.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
MTA-SZTE “Lendület” Fungal Pathogenicity Mechanisms Research Group, Hungarian Academy of Sciences, University of Szeged
(2)
Department of Microbiology, Faculty of Science and Informatics, University of Szeged
(3)
Department of Dermatology and Allergology, Albert Szent-Györgyi Medical Centre, University of Szeged
(4)
Institute of Clinical Microbiology, Albert Szent-Györgyi Medical Centre, University of Szeged

References

  1. Guarro J, Kantarcioglu AS, Horré R, Rodriguez-Tudela JL, Cuenca Estrella M, Berenguer J, et al. Scedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist. Med Mycol. 2006;44:295–327.View ArticlePubMedGoogle Scholar
  2. Cortez KJ, Roilides E, Quiroz-Telles F, Meletiadis J, Antachopoulos C, Knudsen T, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev. 2008;21:157–97.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Tammer I, Tintelnot K, Braun-Dullaeus RC, Mawrin C, Scherlach C, Schlüter D, et al. Infections due to Pseudallescheria/Scedosporium species in patients with advanced HIV disease—a diagnostic and therapeutic challenge. Int J Infect Dis. 2011;15:e422–9.View ArticlePubMedGoogle Scholar
  4. Harun A, Perdomo H, Gilgado F, Chen SC, Cano J, Guarro J, et al. Genotyping of Scedosporium species: a review of molecular approaches. Med Mycol. 2009;47:406–14.View ArticlePubMedGoogle Scholar
  5. Heath CH, Slavin MA, Sorrell TC, Handke R, Harun A, Phillips M, et al. Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. Clin Microbiol Infect. 2009;15:689–93.View ArticlePubMedGoogle Scholar
  6. Chiang CH, Hsu CK, Lee JYY, Chang TC, Hsueh YY, Shieh SJ, et al. Recurrent Scedosporium apiospermum mycetoma successfully treated by surgical excision and voriconazole. Dermatol Sin. 2014;32:29–32.View ArticleGoogle Scholar
  7. White TJ, Bruns T, Lee S, Taylor JW. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, editors. PCR protocols: a guide to methods and applications. New York: Academic Press; 1990. p. 315–22.Google Scholar
  8. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard-2nd ed. CLSI document M38-A2. Wayne: Clinical and Laboratory Standards Institute; 2008.Google Scholar
  9. Ajello L. The isolation of Allescheria boydii shear, an etiologic agent of mycetomas, from soil. Am J Trop Med Hyg. 1952;1:227–38.PubMedGoogle Scholar
  10. Tarozzi G. Ricerche anatomo-patologiehe, baceriologiehet e sperimentali sopra un caso di actinomicosi del piede. Arch Perle Sc Med. 1909;33:553–632.Google Scholar
  11. Gilgado F, Cano J, Gené J, Guarro J. Molecular phylogeny of the Pseudallescheria boydii species complex: proposal of two new species. J Clin Microbiol. 2005;43:4930–42.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Giraud S, Bouchara JP. Scedosporium apiospermum complex: diagnosis and species identification. Curr Fungal Infect Rep. 2014;8:211–9.View ArticleGoogle Scholar
  13. Chen M, Zeng J, De Hoog GS, Stielow B, Gerrits Van Den Ende AH, Liao W, et al. The ‘species complex’ issue in clinically relevant fungi: a case study in Scedosporium apiospermum. Fungal Biol. 2016;120:137–46.View ArticlePubMedGoogle Scholar
  14. Bosma F, Voss A, van Hamersvelt HW, de Sévaux RG, Biert J, Kullberg BJ, et al. Two cases of subcutaneous Scedosporium apiospermum infection treated with voriconazole. Clin Microbiol Infect. 2003;9:750–3.View ArticlePubMedGoogle Scholar
  15. Horré R, Schumacher G, Marklein G, Stratmann H, Wardelmann E, Gilges S, et al. Mycetoma due to Pseudallescheria boydii and co-isolation of Nocardia abscessus in a patient injured in road accident. Med Mycol. 2002;40:525–7.View ArticlePubMedGoogle Scholar
  16. Reimann D, Büssemaker E, Gross P. Successful treatment due to vacuum seal technique of a severe Scedosporium apiospermum skin infection in a renal transplant recipient. Nephrol Dial Transplant. 2004;19:245–8.View ArticlePubMedGoogle Scholar
  17. Tammer I, Seibold M, Krause H, Tintelnot K, König W, König B. Successful topical therapy with voriconazole: pseudallescheriasis after injury. J Trauma. 2007;62:1295–7.View ArticlePubMedGoogle Scholar
  18. Beier F, Kittan N, Holzmann T, Schardt K, Andreesen R, Holler E, et al. Successful treatment of Scedosporium apiospermum soft tissue abscess with caspofungin and voriconazole in a severely immunocompromised patient with acute myeloid leukemia. Transpl Infect Dis. 2010;12:538–42.View ArticlePubMedGoogle Scholar
  19. Montejo M, Muñiz ML, Zárraga S, Aguirrebengoa K, Amenabar JJ, López-Soria L, et al. Infection due to Scedosporium apiospermum in renal transplant recipients: a report of two cases and literature review of central nervous system and cutaneous infections by Pseudallescheria boydiiSc. apiospermum. Mycoses. 2002;45:418–27.View ArticlePubMedGoogle Scholar
  20. Montero LA, Cid A, Fernández CM, Calzadad JM. Lesiones nodulares en retropié en un paciente con trasplante renal. Enferm Infecc Microbiol Clin. 2004;22:551–2.View ArticlePubMedGoogle Scholar
  21. Lemerle E, Bastien M, Demolliens-Dreux G, Forest JL, Boyer E, Chabasse D, et al. Scédosporiose cutanée révélée par un purpura bullo-nécrotique. Ann Dermatol Venereol. 1998;125:711–4.PubMedGoogle Scholar
  22. Eldin C, Chiche L, Thomas G, Dicostanzo MP, Durand JM, Harle JR, et al. Scedosporium apiospermum catheter-related soft-tissue infection: a case report and review of the literature. Med Mycol. 2012;50:627–30.View ArticlePubMedGoogle Scholar
  23. Pether JV, Jones W, Greatorex FB, Bunting W. Acute pyogenic Pseudallescheria boydii foot infection sequentially treated with miconazole and itraconazole. J Infect. 1992;25:335–6.View ArticlePubMedGoogle Scholar
  24. Cunningham R, Mitchell DC. Amphotericin B responsive Scedosporium apiospermum infection in a patient with acute myeloid leukaemia. J Clin Pathol. 1996;49:93–4.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Bower CP, Oxley JD, Campbell CK, Archer CB. Cutaneous Scedosporium apiospermum infection in an immunocompromised patient. J Clin Pathol. 1999;52:846–8.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Gulati V, Bakare S, Tibrewal S, Ismail N, Sayani J, Baghla DPS. A rare presentation of concurrent Scedosporium apiospermum and Madurella grisea eumycetoma in an immunocompetent host. Case Rep Pathol. 2012;2012:154201.PubMedPubMed CentralGoogle Scholar
  27. Rogasi PG, Zanazzi M, Nocentini J, Fantoni E, Trotta M, Faggi E, et al. Disseminated Scedosporium apiospermum infection in renal transplant recipient: long-term successful treatment with voriconazole: a case report. Transplant Proc. 2007;39:2033–5.View ArticlePubMedGoogle Scholar
  28. Sopta J, Atanacković M, Raspopović V, Marković L, Kranjcić-Zec I, Lesić A. Pseudoallescheria boydii (Scedosporium apiospermum), cause of mycotic granulomatous osteomyelitis—case diagnosis. Srp Arh Celok Lek. 2005;133:366–9.View ArticlePubMedGoogle Scholar
  29. Lainščak M, Hočevar A, Logar D, Beović B, Matos T, Tomšič M. Subcutaneous infection with Pseudallescheria boydii in an immunocompromised patient. Clin Rheumatol. 2007;26:1023–4.View ArticlePubMedGoogle Scholar
  30. Kantarcioğlu SA, Yücel A. Pseudallescheriasis cases identified at department of microbiology and clinical microbiology, Cerrahpasa Medical Faculty and European Confederation of Medical Mycology (ECMM) Pseudallescheriasis Study Group. Cerrahpaşa J Med. 2005;36:90–6.Google Scholar
  31. Taşbakan MI, Önal U, Metin DY, Pullukçu H, Yamazhan T, Çeltik A, et al. A rare cause of soft tissue infections: Pseudallescheria boydii. J Microbiol Infect Dis. 2015;5:176–9.Google Scholar
  32. Török L, Simon G, Csornai A, Tápai M, Török I. Scedosporium apiospermum infection imitating lymphocutaneous sporotrichosis in a patient with myeloblastic–monocytic leukaemia. Br J Dermatol. 1995;133:805–9.View ArticlePubMedGoogle Scholar
  33. Béraud G, Desbois N, Coyo C, Quist D, Rozé B, Savorit L, et al. Paradoxical response preceding control of Scedosporium apiospermum mycetoma with posaconazole treatment. Infect Dis. 2015;47:830–3.View ArticleGoogle Scholar
  34. Porte L, Khatibi S, Hajj LE, Cassaing S, Berry A, Massip P, et al. Scedosporium apiospermum mycetoma with bone involvement successfully treated with voriconazole. Trans R Soc Trop Med Hyg. 2006;100:891–4.View ArticlePubMedGoogle Scholar
  35. Ng TT, Robson GD, Denning DW. Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology. 1994;140:2475–9.View ArticlePubMedGoogle Scholar
  36. Valenzuela Salas I, Martinez Peinado C, Fernandez Miralbell A, Soto Diaz A, Nogueras Morillas P, Martin Castro A, et al. Skin infection caused by Scedosporium apiospermum in immunocompromised patients. Report of two cases. Dermatol Online J. 2013;19:20022.PubMedGoogle Scholar

Copyright

© The Author(s) 2017

Advertisement